Wyeth-Ayerst Laboratories announced
recently that thousands of patients affected by acute myeloid leukemia (AML) may
benefit from the new National Comprehensive Cancer Network (NCCN) guidelines for
the appropriate treatment of AML, including the use of gemtuzumab ozogamicin (Mylotarg)
in specific clinical situations. The only antibody-targeted chemotherapeutic
agent approved by the US Food and Drug Administration, gemtuzumab is indicated
for patients with CD33-positive AML in first relapse who are 60 years of
age or older and who are not considered candidates for other cytotoxic
chemotherapy. The safety and efficacy of this agent in patients with poor
performance status and organ dysfunction has not been established.
"We are pleased about the inclusion of Mylotarg in the NCCN
guidelines because it shows that this innovative technology is having an impact
in real clinical practice," said Harold K. Marder, md, senior vice
president of Global Medical Affairs, Wyeth-Ayerst Laboratories. "Targeted
therapies are an important component of the future of cancer treatment, and
Wyeth is committed to researching and developing drugs like Mylotarg that
provide effective, tolerable treatments for patients with deadly cancers."
Guidelines Updated Annually
Founded in 1995, the NCCN is dedicated to advancing the mission
of its member institutions in education, research, and patient care. The
organization’s annually updated practice guidelines are recognized as the
standard for clinical policy in oncology.
"We provide the entire professional oncology community with
treatment recommendations based on the experience of our member
institutions," said William T. McGivney, phd, CEO of the NCCN. "The
landscape of cancer treatment is constantly changing, and we are committed to
keeping oncologists on the cutting edge."
The NCCN AML Guidelines are available through the NCCN. For more
information, call the NCCN at (215) 728-4788 or contact them at www.NCCN.org.